Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials

  Placebo (n =  515) Ertugliflozin 5 mg (n = 519) Ertugliflozin 15 mg (n = 510)
Age, years 56.9 (9.6) 57.4 (9.6) 57.5 (9.7)
Male, n (%) 280 (54.4) 267 (51.4) 265 (52.0)
BMI, kg/m2 31.3 (6.0) 31.6 (6.0) 31.5 (5.4)
Race, n (%)
 White 378 (73.4) 382 (73.6) 374 (73.3)
 Asian 79 (15.3) 77 (14.8) 77 (15.1)
 Black or African American 31 (6.0) 34 (6.6) 37 (7.3)
 Other 27 (5.2) 26 (5.0) 22 (4.3)
Duration of T2DM, years 7.4 (5.9) 7.6 (6.1) 7.6 (5.7)
HbA1c, %a 8.1 (0.9) 8.1 (0.9) 8.2 (1.0)
eGFR, mL/min/1.73 m2 89.5 (19.1) 88.2 (17.7) 89.0 (18.5)
Medical history of hypertension, n (%) 349 (67.8) 358 (69.0) 344 (67.4)
Sitting SBP, mmHgb
 Mean (SD) 129.7 (14.5) 131.0 (13.3) 130.5 (13.0)
 ≤ 130, n (%) 268 (53.2) 244 (47.7) 249 (49.6)
 > 130, n (%) 236 (46.8) 268 (52.3) 253 (50.4)
 ≤ 140, n (%) 388 (77.0) 392 (76.6) 383 (76.3)
 > 140, n (%) 116 (23.0) 120 (23.4) 119 (23.7)
Sitting DBP, mmHgb 78.0 (7.5) 78.4 (7.9) 78.4 (7.5)
Pulse rate, bpm 72.6 (9.2) 72.8 (10.0) 72.6 (9.3)
Microvascular diseasec, n (%) 85 (16.5) 90 (17.3) 86 (16.9)
Antihypertensive therapy used, n (%)d
 Any 313 (60.8) 326 (62.8) 308 (60.4)
 Diuretics 31 (6.0) 41 (7.9) 38 (7.5)
 RAAS blockers 282 (54.8) 293 (56.5) 278 (54.5)
 β blockers 127 (24.7) 113 (21.8) 105 (20.6)
 Calcium channel blockers 12 (2.3) 10 (1.9) 13 (2.6)
  1. Data presented as mean (SD), unless otherwise specified
  2. BMI body mass index, bpm beats per minute, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, RAAS renin–angiotensin–aldosterone system, SBP systolic blood pressure, SD standard deviation, T2DM type 2 diabetes mellitus
  3. aNumber of patients with data: 512 (placebo), 515 (ertugliflozin 5 mg), 504 (ertugliflozin 15 mg)
  4. bNumber of patients with data: 504 (placebo), 512 (ertugliflozin 5 mg), 502 (ertugliflozin 15 mg)
  5. cIncluded preferred terms defined by a sponsor-generated custom Medical Dictionary for Regulatory Activities (MeDRA) query reported as medical history related to diabetic microvascular complications (Additional file 1)
  6. dSome patients took more than one hypertension therapy at baseline